Literature DB >> 15204672

Challenges in increasing access to buprenorphine treatment for opiate addiction.

Joyce C West1, Thomas R Kosten, Joshua Wilk, Dace Svikis, Elise Triffleman, Donald S Rae, William E Narrow, Farifteh F Duffy, Darrel A Regier.   

Abstract

The aims of this study are to assess psychiatrists' comfort using office-based opiate agonist treatment (OBOT) and to identify psychiatrist characteristics associated with OBOT comfort. A random sample of 2,323 AMA Masterfile of Physicians psychiatrists were surveyed through the 2002 APIRE National Survey of Psychiatric Practice (NSSP). Of the 52% responding (N = 1,203), 80.6% (SE = 1.8%) were not comfortable providing OBOT. Males, addiction-certified psychiatrists, and those treating substance abuse patients were more comfortable providing OBOT. These findings highlight significant barriers in providing buprenorphine treatment. Increasing the understanding of specific financing and services delivery barriers that clinicians face is needed to inform the development of effective integrated services models and policies to facilitate OBOT implementation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15204672     DOI: 10.1080/10550490490440753

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  17 in total

1.  Improving treatment for opioid dependence: a perspective from the Ohio Valley node of the NIDA Clinical Trials Network.

Authors:  Erin L Winstanley; Greg S Brigham; Dean Babcock; Theresa Winhusen
Journal:  Prog Community Health Partnersh       Date:  2014

2.  Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency.

Authors:  Joji Suzuki; Hilary S Connery; Tatyana V Ellison; John A Renner
Journal:  Am J Addict       Date:  2014-07-25

3.  States' implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Jennifer R Havens; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

4.  Barriers to primary care physicians prescribing buprenorphine.

Authors:  Eliza Hutchinson; Mary Catlin; C Holly A Andrilla; Laura-Mae Baldwin; Roger A Rosenblatt
Journal:  Ann Fam Med       Date:  2014 Mar-Apr       Impact factor: 5.166

5.  The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2014-05       Impact factor: 2.582

6.  The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis.

Authors:  Hannah K Knudsen
Journal:  J Stud Alcohol Drugs       Date:  2015-07       Impact factor: 2.582

7.  The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.

Authors:  James E Egan; Paul Casadonte; Tracy Gartenmann; Judith Martin; Elinore F McCance-Katz; Julie Netherland; John A Renner; Linda Weiss; Andrew J Saxon; David A Fiellin
Journal:  J Gen Intern Med       Date:  2010-05-11       Impact factor: 5.128

8.  HIV provider endorsement of primary care buprenorphine treatment: a vignette study.

Authors:  Hillary V Kunins; Nancy L Sohler; Robert J Roose; Chinazo O Cunningham
Journal:  Fam Med       Date:  2009 Nov-Dec       Impact factor: 1.756

9.  Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.

Authors:  Alexander Y Walley; Julie K Alperen; Debbie M Cheng; Michael Botticelli; Carolyn Castro-Donlan; Jeffrey H Samet; Daniel P Alford
Journal:  J Gen Intern Med       Date:  2008-09       Impact factor: 5.128

10.  Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians.

Authors:  Chinazo O Cunningham; Hillary V Kunins; Robert J Roose; Rashiah T Elam; Nancy L Sohler
Journal:  J Gen Intern Med       Date:  2007-07-10       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.